Meeting NewsVideo

VIDEO: Gilead reports phase 2 safety, efficacy of GS-9674 for NASH

SAN FRANCISCO — In this exclusive video perspective from The Liver Meeting 2018, Rob Myers, MD, senior director of the liver diseases therapeutic area at Gilead Sciences, discusses the company’s therapeutic pipeline for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

“We’re focused on patients who have advanced fibrosis due to NASH ... because we believe these patients have the greatest unmet need,” Myers told Healio Gastroenterology and Liver Disease. “We’re happy to report that we now have data from phase 2 studies that all three of our oral agents for the treatment of NASH have demonstrated activity and safety.”

Myers discussed data presented on GS-9674, a farnesoid X receptor (FXR) agonist, designed for the treatment of patients with NASH and fibrosis stage 3 or stage 4.

Results showed that 39% of patients had a decline in MRI-PDFF of 30% or more compared with placebo. Treated patients also demonstrated significant reductions in serum gamma-glutamyl transferase and pharmacodynamic markers of FXR activation. GS-9674 was well-tolerated.

Additionally, Myers stated that Gilead has fully enrolled patients in a phase 2 study of combination therapies for NASH. They expect to report study results by the end of 2019.

Reference:

Patel K, et al. Abstract 0736. Presented at: The Liver Meeting 2018; Nov. 9-13, 2018; San Francisco.

Disclosure: Myers is the senior director of the liver diseases therapeutic area at Gilead Sciences.

SAN FRANCISCO — In this exclusive video perspective from The Liver Meeting 2018, Rob Myers, MD, senior director of the liver diseases therapeutic area at Gilead Sciences, discusses the company’s therapeutic pipeline for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

“We’re focused on patients who have advanced fibrosis due to NASH ... because we believe these patients have the greatest unmet need,” Myers told Healio Gastroenterology and Liver Disease. “We’re happy to report that we now have data from phase 2 studies that all three of our oral agents for the treatment of NASH have demonstrated activity and safety.”

Myers discussed data presented on GS-9674, a farnesoid X receptor (FXR) agonist, designed for the treatment of patients with NASH and fibrosis stage 3 or stage 4.

Results showed that 39% of patients had a decline in MRI-PDFF of 30% or more compared with placebo. Treated patients also demonstrated significant reductions in serum gamma-glutamyl transferase and pharmacodynamic markers of FXR activation. GS-9674 was well-tolerated.

Additionally, Myers stated that Gilead has fully enrolled patients in a phase 2 study of combination therapies for NASH. They expect to report study results by the end of 2019.

Reference:

Patel K, et al. Abstract 0736. Presented at: The Liver Meeting 2018; Nov. 9-13, 2018; San Francisco.

Disclosure: Myers is the senior director of the liver diseases therapeutic area at Gilead Sciences.

    See more from The Liver Meeting